DR-M has significantly higher annualized costs than either FSM or CR-M. Potential clinical benefits (improved diagnostic accuracy, shorter examination time, lower radiation dose) for patients, institutions and payers have not been demonstrated in a clinical setting. The ability to detect cancer is comparable for DR-M and FSM. (There is not sufficient data on clinical effectiveness of CR-M). Assuming that DR-M and CR-M are, at best, clinically equivalent to FSM, the minimum-cost system is preferred; therefore, conventional FSM is preferable to DM at this time.